Corvus Pharmaceuticals Management
Management criteria checks 2/4
Corvus Pharmaceuticals' CEO is Rick Miller, appointed in Feb 2014, has a tenure of 11.25 years. total yearly compensation is $3.07M, comprised of 1.1% salary and 98.9% bonuses, including company stock and options. directly owns 3.41% of the company’s shares, worth $9.18M. The average tenure of the management team and the board of directors is 8 years and 9.4 years respectively.
Key information
Rick Miller
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 1.06% |
| CEO tenure | 11.3yrs |
| CEO ownership | 3.4% |
| Management average tenure | 8yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Mar 28Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance
Mar 03We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
Jan 13
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Dec 18Corvus Pharmaceuticals: The Market Likes The Story
Nov 13Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$41m |
| Dec 31 2024 | US$3m | US$33k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$23m |
| Mar 31 2024 | n/a | n/a | -US$25m |
| Dec 31 2023 | US$1m | US$110k | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$300k | -US$47m |
Compensation vs Market: Rick's total compensation ($USD3.07M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Miller (73 yo)
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$3.07m | 3.41% $ 9.2m | |
| Co-Founder & Independent Director | no data | US$72.27k | 0% $ 0 | |
| Chief Financial Officer | 10.5yrs | US$1.61m | 0.41% $ 1.1m | |
| Senior Vice President of Pharmaceutical Development | 5.4yrs | US$1.57m | 0.23% $ 607.4k | |
| Senior VP & Chief Business Officer | 1.3yrs | no data | no data |
Experienced Management: CRVS's management team is seasoned and experienced (8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$3.07m | 3.41% $ 9.2m | |
| Co-Founder & Independent Director | 10.5yrs | US$72.27k | 0% $ 0 | |
| Independent Director | 10.5yrs | US$78.27k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0.23% $ 632.0k | |
| Independent Director | 6.3yrs | US$74.27k | 0.015% $ 39.5k | |
| Independent Director | 8.3yrs | US$70.27k | 0% $ 0 | |
| Independent Director | 9.4yrs | US$86.27k | 0% $ 0 |
Experienced Board: CRVS's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 01:58 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corvus Pharmaceuticals, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dane Leone | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Vamil Divan | Credit Suisse |